Atrial fibrillation following subconjunctival injection of mydricaine number 02

Simple item page
dc.contributor.authorKeembiyage, R.
dc.contributor.authorRaymond, G.
dc.contributor.authorNewland, H.
dc.date.issued2006
dc.description.abstractMydricaine is a mydriatic agent used as a subconjunctival injection to maintain perioperative mydriasis. The drug consists of a mixture of 1.3 mg atropine sulphate, 0.12 mg adrenaline and 8.4 mg procaine hydrochloride in a single vial of 0.4 mL. It is common practice to use mydricaine injections during vitreoretinal surgery in the Royal Adelaide Hospital. Even though the drug is used widely in many vitreoretinal centres, mydricaine is not listed in the British National Formulary nor Monthly Index of Medical Specialities. Therefore, case reports provide the main forum for reporting side-effects.
dc.identifier.citationClinical and Experimental Ophthalmology, 2006; 34(8):806-808
dc.identifier.doi10.1111/j.1442-9071.2006.01331.x
dc.identifier.issn1442-6404
dc.identifier.issn1442-9071
dc.identifier.urihttp://hdl.handle.net/2440/23077
dc.language.isoen
dc.publisherBlackwell Publishing
dc.source.urihttps://doi.org/10.1111/j.1442-9071.2006.01331.x
dc.subjectTachycardia
dc.titleAtrial fibrillation following subconjunctival injection of mydricaine number 02
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Public Health publications